Biotech

All Articles

Zephyrm seeks Hong Kong IPO to money period 3 tissue treatment trials

.Zephyrm Bioscience is gusting towards the Hong Kong stock market, declaring (PDF) for an IPO to ban...

Frazier Lifestyle Sciences gets $630M for little, mid-cap biotechs

.Frazier Daily life Sciences has sourced an even further $630 million for its own fund focused on sm...

GigaGen garners approximately $135M BARDA bucks to hammer botulism

.Antitoxin enthusiast GigaGen, a subsidiary of Spanish biopharma Grifols, is increase its own techno...

GPCR firm Septerna apply for IPO on strength of preclinical data

.Septerna will learn exactly how a biotech without "any purposeful professional information" meals i...

Kurma shuts first $154M haul for greatest biotech fund yet

.European VC company Kurma Allies has actually unveiled its own latest biotech fund, along with 140 ...

Prothena advertises one officer while yet another leaves behind-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our roundup of significant leadership hirings, firings a...

Editas capitalize Tip Cas9 licensing rights for $57M

.Versus the background of a Cas9 patent struggle that refuses to pass away, Editas Medication is cas...

Ultragenyx changes gene therapy application to call up effectiveness

.A minority of clients taking Ultragenyx Pharmaceutical's Wilson disease gene therapy UX701 have act...

Biopharma discharge fee maintains in Q3: Strong Biotech review

.As summertime heat energy counts on cool winds, really hopes that this year would certainly bring c...

J &amp J drops phase 2 dengue prospect in newest shift from injections

.Johnson &amp Johnson's deprioritization of its contagious illness pipe has asserted yet another pre...